Portfolio Updates
1.7 Million Americans Are Impacted by Sepsis Each Year
Early detection can mean the difference between life and death. Why Exit 156 invested in Vail Scientific's vSNO sepsis screening device.
1.7 million Americans are impacted by sepsis each year - and early detection can mean the difference between life and death.
That’s why in February 2025 we announced our investment in Vail Scientific, LLC, a company aiming to redefine how we detect and respond to sepsis. Their vSNO™ Sepsis Screening Device, developed in partnership with Minnetronix Medical, is a major step toward faster, noninvasive sepsis detection - something that could transform patient outcomes.
➡️ Curious about how this game-changing tech is coming to life? Check out the full story here: https://lnkd.in/gXAJ5iu9
Keep Reading
Related Stories
Portfolio Updates
Advancing Sepsis Detection: The VSNO Breath Analyzer
Vail Scientific's VSNO Breath Analyzer offers rapid, non-invasive sepsis screening in as little as two minutes, developed with Minnetronix Medical.
April 29, 2025Read More
Firm News
3 Bold Predictions for Health Systems in 2025
Epic's dominance is ending. Rural healthcare is reaching a breaking point. Consolidation is backfiring. Exit 156's take on where health systems are headed.
June 18, 2025Read More
Press
Exit 156 featured in Medical Alley
Exit 156 and the Humla Health partnership covered by Medical Alley. A look at how the firm is transforming healthcare staffing.
May 27, 2025Read More